In this prostate cancer–focused tumor board brief, Dr. Neeraj Agarwal (GU Medical Oncologist, University of Utah Huntsman Cancer Institute), Dr. Parth Modi (Urologic Oncologist), and Dr. Tyler Seibert (Radiation Oncologist) come together to discuss contemporary management approaches across the spectrum of localized prostate cancer, with a focus on low-risk and Grade Group 1 disease.
The panel begins by reviewing the principles of active surveillance, including how urologists and radiation oncologists counsel patients, the importance of accurate risk stratification, and the role of MRI in initial assessment. They explore how adjunctive molecular testing can support decision-making in borderline cases such as Grade Group 2 disease, and how these tools integrate with biopsy and imaging data.
For patients electing local therapy, Dr. Seibert discusses current radiation techniques, preferred fractionation schedules, and the use of modern supportive technologies that improve precision and minimize toxicity. The conversation highlights how multidisciplinary collaboration helps individualize care and ensures patients receive evidence-based guidance tailored to their risk category and personal goals.
Contributors:
Dr. Neeraj Agarwal is a professor of medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI.
Dr. Parth Modi is a urologic oncologist at the University of Chicago in Chicago, Illinois.
Dr. Tyler Seibert is a radiation oncologist and Assistant Professor in the the Division of Radiation Oncology at UC San Diego School of Medicine in San Diego, California.
